Literature DB >> 17662632

Relationship of circulating total homocysteine and C-reactive protein to trabecular bone in postmenopausal women.

Shilpa N Bhupathiraju1, D Lee Alekel, Jeanne W Stewart, Laura N Hanson, Kristine M Shedd, Manju B Reddy, Kathy B Hanson, Marta D Van Loan, Ulrike Genschel, Kenneth J Koehler.   

Abstract

Homocysteine (Hcy) and C-reactive protein (CRP) are novel risk factors for osteoporosis. The purpose of this analysis was to determine the relationship of Hcy and CRP to volumetric trabecular bone, but also to assess their relationship to areal composite bone in healthy postmenopausal women (N=184). We used peripheral quantitative computed tomography to assess volumetric bone at the distal tibia and dual-energy X-ray absorptiometry to assess areal composite bone at the proximal femur and lumbar spine. Multiple regression revealed that 22% of the variability in trabecular bone mineral content (F=9.59, p<or=0.0001) was accounted for by weight (12.4%; p<or=0.0001), hemoglobin (5.5%; p=0.0006), uric acid (4.2%; p=0.003), and blood glucose (1.5%; p=0.07). Multiple regression revealed that 5.4% of the variability in trabecular bone mineral density (F=3.36; p=0.020) was accounted for by hemoglobin (4.2%; p=0.006) and Hcy (1.5%; not significant, p=0.10). Total Hcy and CRP were not significantly related to trabecular bone, perhaps because these were nonosteoporotic women. However, our results suggested a weak but negative relationship between Hcy and trabecular bone. Further investigation is needed to examine the relationship of Hcy as an endogenous bioactive molecule to trabecular bone loss in early postmenopausal women and the response of trabecular bone to dietary intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662632      PMCID: PMC2131712          DOI: 10.1016/j.jocd.2007.06.002

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  35 in total

Review 1.  Follow-up report on the diagnosis of diabetes mellitus.

Authors:  Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

2.  Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.

Authors:  M Hummel; D Buchheidt; S Reiter; J Bergmann; R Hofheinz; R Hehlmann
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

3.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 4.  High-sensitivity C-reactive protein: clinical importance.

Authors:  Shari S Bassuk; Nader Rifai; Paul M Ridker
Journal:  Curr Probl Cardiol       Date:  2004-08       Impact factor: 5.200

5.  Increased plasma homocysteine after menopause.

Authors:  A E Hak; K H Polderman; I C Westendorp; C Jakobs; A Hofman; J C Witteman; C D Stehouwer
Journal:  Atherosclerosis       Date:  2000-03       Impact factor: 5.162

6.  Women and cardiovascular risk.

Authors:  F K Welty
Journal:  Am J Cardiol       Date:  2001-10-11       Impact factor: 2.778

7.  Demographic, health, lifestyle, and blood vitamin determinants of serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Vijay Ganji; Mohammmad R Kafai
Journal:  Am J Clin Nutr       Date:  2003-04       Impact factor: 7.045

8.  Homocysteine as a predictive factor for hip fracture in older persons.

Authors:  Robert R McLean; Paul F Jacques; Jacob Selhub; Katherine L Tucker; Elizabeth J Samelson; Kerry E Broe; Marian T Hannan; L Adrienne Cupples; Douglas P Kiel
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

9.  Homocysteine levels and the risk of osteoporotic fracture.

Authors:  Joyce B J van Meurs; Rosalie A M Dhonukshe-Rutten; Saskia M F Pluijm; Marjolein van der Klift; Robert de Jonge; Jan Lindemans; Lisette C P G M de Groot; Albert Hofman; Jacqueline C M Witteman; Johannes P T M van Leeuwen; Monique M B Breteler; Paul Lips; Huibert A P Pols; André G Uitterlinden
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

10.  Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation.

Authors:  Nader Rifai; Paul M Ridker
Journal:  Clin Chem       Date:  2003-04       Impact factor: 8.327

View more
  9 in total

1.  The effects of Acanthopanax senticosus extract on bone turnover and bone mineral density in Korean postmenopausal women.

Authors:  You-Cheol Hwang; In-Kyung Jeong; Kyu Jeung Ahn; Ho Yeon Chung
Journal:  J Bone Miner Metab       Date:  2009-05-20       Impact factor: 2.626

2.  Relation of plasma total homocysteine, folate and vitamin B12 levels to bone mineral density in Moroccan healthy postmenopausal women.

Authors:  Zhor Ouzzif; Khalid Oumghar; Karim Sbai; Aziza Mounach; El Mustapha Derouiche; Abdellah El Maghraoui
Journal:  Rheumatol Int       Date:  2010-07-31       Impact factor: 2.631

3.  Uric acid and bone mineral density in postmenopausal osteoporotic women: the link lies within the fat.

Authors:  M Pirro; M R Mannarino; V Bianconi; S De Vuono; A Sahebkar; F Bagaglia; L Franceschini; A M Scarponi; E Mannarino; T Merriman
Journal:  Osteoporos Int       Date:  2016-10-10       Impact factor: 4.507

4.  Circulating Serum Amyloid A, hs-CRP and Vitamin D Levels in Postmenopausal Osteoporosis.

Authors:  Anahid Safari; Afshin Borhani-Haghighi; Mehdi Dianatpour; Seyed Taghi Heydari; Farzaneh Foroughinia; Gholamhossein Ranjbar Omrani
Journal:  Galen Med J       Date:  2019-10-09

5.  Androidal fat dominates in predicting cardiometabolic risk in postmenopausal women.

Authors:  O A Matvienko; D L Alekel; S N Bhupathiraju; H Hofmann; L M Ritland; M B Reddy; M D Van Loan; C D Perry
Journal:  Cardiol Res Pract       Date:  2010-12-19       Impact factor: 1.866

6.  Effects of Calcium Fructoborate on Levels of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, and MCP-1: a Double-blind, Placebo-controlled Clinical Study.

Authors:  Otilia-Constantina Rogoveanu; George Dan Mogoşanu; Cornelia Bejenaru; Ludovic Everard Bejenaru; Octavian Croitoru; Johny Neamţu; Zbigniew Pietrzkowski; Tania Reyes-Izquierdo; Andrei Biţă; Iulia Daria Scorei; Romulus Ion Scorei
Journal:  Biol Trace Elem Res       Date:  2014-11-30       Impact factor: 3.738

7.  High-sensitivity CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: the MrOS Sweden study.

Authors:  Anna L Eriksson; Sofia Movérare-Skrtic; Östen Ljunggren; Magnus Karlsson; Dan Mellström; Claes Ohlsson
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

8.  Interferon (IFN)-γ-mediated inflammation and the kynurenine pathway in relation to bone mineral density: the Hordaland Health Study.

Authors:  E M Apalset; C G Gjesdal; P M Ueland; Ø Midttun; A Ulvik; G E Eide; K Meyer; G S Tell
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

9.  Hyperhomocysteinemia is Associated with Inflammation, Bone Resorption, Vitamin B12 and Folate Deficiency and MTHFR C677T Polymorphism in Postmenopausal Women with Decreased Bone Mineral Density.

Authors:  Massimo De Martinis; Maria Maddalena Sirufo; Cristina Nocelli; Lara Fontanella; Lia Ginaldi
Journal:  Int J Environ Res Public Health       Date:  2020-06-15       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.